Form 8-K - Current report:
SEC Accession No. 0001104659-23-057504
Filing Date
2023-05-09
Accepted
2023-05-09 08:35:12
Documents
16
Period of Report
2023-05-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2315099d1_8k.htm   iXBRL 8-K 24869
2 EXHIBIT 99.1 tm2315099d1_ex99-1.htm EX-99.1 4370
6 GRAPHIC tm2315099d1_ex99-1img002.jpg GRAPHIC 2436
7 GRAPHIC tm2315099d1_ex99-1img001.jpg GRAPHIC 1600
8 GRAPHIC tm2315099d1_ex99-1img003.jpg GRAPHIC 1076
  Complete submission text file 0001104659-23-057504.txt   210005

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tmb-20230505.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tmb-20230505_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tmb-20230505_pre.xml EX-101.PRE 22594
10 EXTRACTED XBRL INSTANCE DOCUMENT tm2315099d1_8k_htm.xml XML 3488
Mailing Address 375 PHEASANT RUN NEWTOWN PA 18940
Business Address 375 PHEASANT RUN NEWTOWN PA 18940 267-759-3681
Onconova Therapeutics, Inc. (Filer) CIK: 0001130598 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36020 | Film No.: 23900140
SIC: 2834 Pharmaceutical Preparations